Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03270059 · ClinicalTrials.gov registry record · Phase 2
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
A Phase 2 study of Metastatic Malignant Neoplasm in the Brain and Central Nervous System Neoplasm, sponsored by OHSU Knight Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03270059 is a Phase 2 study of Metastatic Malignant Neoplasm in the Brain and Central Nervous System Neoplasm that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 150 participants, above the 85-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03270059, a Phase 2 study of Metastatic Malignant Neoplasm in the Brain and Central Nervous System Neoplasm, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.
Conditions Studied
Interventions
- DRUG Ferumoxytol
- PROCEDURE Magnetic Resonance Imaging
- DRUG Gadolinium
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-10-06 |
| Est. Completion | 2028-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03270059
The ClinicalTrials.gov registry entry for NCT03270059 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 85-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (76% higher). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 3 interventions - of which Ferumoxytol is the first listed.
NCT03270059 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT03270059 about?
NCT03270059 is a clinical study titled "Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System". This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervou...
What is the current status of trial NCT03270059?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2017-10-06. Estimated completion is 2028-12-15.
What conditions does trial NCT03270059 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain, Central Nervous System Neoplasm, Cranial Nerve Disorder.
What interventions are being tested in trial NCT03270059?
The interventions under investigation include: Ferumoxytol (DRUG), Magnetic Resonance Imaging (PROCEDURE), Gadolinium (DRUG).
Who is sponsoring clinical trial NCT03270059?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03270059 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm in the Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
RECRUITING · Phase 2
-
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RECRUITING · Phase 2
-
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
RECRUITING · Phase 2
-
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Malignant Neoplasm in the Brain
All registered trials for this condition
Central Nervous System Neoplasm
All registered trials for this condition
Oregon
All trials with a study site in Oregon
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.